MA29448B1 - Composition pharmaceutique contenant des gestagenes et/ou des oestrogenes et du 5-methyl-(6s)-tetrahydrofolate - Google Patents
Composition pharmaceutique contenant des gestagenes et/ou des oestrogenes et du 5-methyl-(6s)-tetrahydrofolateInfo
- Publication number
- MA29448B1 MA29448B1 MA30367A MA30367A MA29448B1 MA 29448 B1 MA29448 B1 MA 29448B1 MA 30367 A MA30367 A MA 30367A MA 30367 A MA30367 A MA 30367A MA 29448 B1 MA29448 B1 MA 29448B1
- Authority
- MA
- Morocco
- Prior art keywords
- deficit
- tetrahydrofolate
- methyl
- folate
- induced
- Prior art date
Links
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000583 progesterone congener Substances 0.000 title abstract 2
- 230000006735 deficit Effects 0.000 abstract 4
- 229940014144 folate Drugs 0.000 abstract 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 3
- 235000019152 folic acid Nutrition 0.000 abstract 3
- 239000011724 folic acid Substances 0.000 abstract 3
- 206010010356 Congenital anomaly Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032170 Congenital Abnormalities Diseases 0.000 abstract 1
- 241000282324 Felis Species 0.000 abstract 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 abstract 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 abstract 1
- 208000006038 Urogenital Abnormalities Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000276 neural tube Anatomy 0.000 abstract 1
- 229940127234 oral contraceptive Drugs 0.000 abstract 1
- 239000003539 oral contraceptive agent Substances 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE CONTENANT DES GESTAGÈNES, DE PRÉFÉRENCE DE LA DROSPIRÉNONE, DES OESTROGÈNES, DE PRÉFÉRENCE DE L'ÉTHINYLESTRADIOL ET DU 5-MÉTHYL-(6S)-TÉTRAHYDROFOLATE, QUI PEUT ÊTRE UTILISÉE COMME CONTRACEPTIF ORAL ET QUI PEUT AINSI PRÉVENIR DES MALADIES INDUITES PAR UN DÉFICIT EN FOLATE CHEZ DES CONSOMMATRICES, EN PARTICULIER DES MALADIES CARDIO-VASCULAIRES ET, APRÈS LA CONCEPTION DE L'EMBRYON, DES MALFORMATIONS CONGÉNITALES INDUITES PAR UN DÉFICIT EN FOLATE, TELLES QUE DES ANOMALIES DU TUBE NEURAL, DES ANOMALIES DES VENTRICULES, DES ANOMALIES UROGÉNITALES, AINSI QUE DES BECS-DE-LIÈVRE, SANS MASQUER LES SYMPTÔMES D'UN DÉFICIT EN VITAMINE B12. EN CAS D'UN POLYMORPHISME HOMOZYGOTE OU HÉTÉROZYGOTE DE LA MÉTHYLÈNE TÉTRAHYDROFOLATE RÉDUCTASE, CETTE COMPOSITION FACILITE LA CAPACITÉ D'UTILISATION ILLIMITÉE DES COMPOSANTS DE FOLATE 5-MÉTHYL-(6S)-TÉTRAHYDROFOLATE PAR L'ORGANISME ET AINSI LEUR ACTIVITÉ BIOLOGIQUE, AFIN D'ÉVITER LES MALFORMATIONS CONGÉNITALES INDUITES PAR UN DÉFICIT EN FOLATE SUSMENTIONNÉES. APRÈS ARRÊT DU CONTRACEPTIF, UNE ACTION PROTECTRICE PERSISTANT PLUS LONGTEMPS EST MAINTENUE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005023301A DE102005023301B4 (de) | 2005-05-13 | 2005-05-13 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
| DE102006016285A DE102006016285A1 (de) | 2006-04-03 | 2006-04-03 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29448B1 true MA29448B1 (fr) | 2008-05-02 |
Family
ID=37396913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30367A MA29448B1 (fr) | 2005-05-13 | 2007-11-13 | Composition pharmaceutique contenant des gestagenes et/ou des oestrogenes et du 5-methyl-(6s)-tetrahydrofolate |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US20080160004A1 (fr) |
| EP (3) | EP2116249B2 (fr) |
| JP (2) | JP2008540482A (fr) |
| KR (2) | KR20080028369A (fr) |
| CN (2) | CN101198332B (fr) |
| AR (1) | AR054123A1 (fr) |
| AT (2) | ATE555791T1 (fr) |
| AU (1) | AU2006245921A1 (fr) |
| BR (1) | BRPI0611443B8 (fr) |
| CA (1) | CA2608639C (fr) |
| CL (2) | CL2009002187A1 (fr) |
| CR (1) | CR9531A (fr) |
| CY (2) | CY1109261T1 (fr) |
| DE (1) | DE502006003617D1 (fr) |
| DK (2) | DK2116249T3 (fr) |
| DO (1) | DOP2006000110A (fr) |
| EA (2) | EA028530B1 (fr) |
| EC (1) | ECSP078001A (fr) |
| ES (2) | ES2387525T5 (fr) |
| GT (1) | GT200600200A (fr) |
| HR (1) | HRP20090418T1 (fr) |
| IL (1) | IL187340A (fr) |
| MA (1) | MA29448B1 (fr) |
| MY (1) | MY147362A (fr) |
| NO (1) | NO345807B1 (fr) |
| PE (1) | PE20061415A1 (fr) |
| PL (2) | PL2116249T3 (fr) |
| PT (2) | PT1888077E (fr) |
| RS (2) | RS50972B (fr) |
| SG (1) | SG169973A1 (fr) |
| SI (2) | SI2116249T1 (fr) |
| SV (1) | SV2008002527A (fr) |
| TN (1) | TNSN07418A1 (fr) |
| TW (1) | TWI380820B (fr) |
| UY (1) | UY29527A1 (fr) |
| WO (1) | WO2006120035A2 (fr) |
| ZA (2) | ZA200710811B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| EP1891959A1 (fr) * | 2006-08-14 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Préparations contraceptives pour diminuer le risque d'erreurs innées |
| DE112007001600A5 (de) * | 2006-07-06 | 2009-04-30 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
| BRPI0810049A2 (pt) * | 2007-04-05 | 2015-05-05 | Bayer Schering Pharma Ag | Regime de drospirenona/17beta-estradiol, produto de combinação farmacêutica e kit para realizar esse regime |
| EA201070715A1 (ru) * | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
| TW200946542A (en) * | 2008-03-10 | 2009-11-16 | Vladimir Hanes | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
| WO2009112231A2 (fr) * | 2008-03-10 | 2009-09-17 | Schuermann Rolf | Nouveau régime posologique de drospirénone/17β-estradiol, produit de combinaison pharmaceutique, et nécessaire pour appliquer ce régime posologique |
| MX356702B (es) | 2010-04-15 | 2018-06-11 | Bayer Ip Gmbh | Formas de dosificación sólidas orales con dosis muy bajas para la hrt. |
| EP2383279A1 (fr) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Procédé de préparation d'estetrol |
| EP2617422A1 (fr) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Activité anti-tumeur de folates réduites comme tetrahydrofolate de methylène, tetrahydrofolate ou tetrahydrofolate de methyle |
| EP2781214A1 (fr) * | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation de calcium amorphe L-5-méthyltétrahydrofolate (L-5-MTHF-Ca) |
| CN104490887A (zh) * | 2014-09-04 | 2015-04-08 | 连云港金康和信药业有限公司 | (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物 |
| RS57328B1 (sr) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| NZ737945A (en) | 2015-06-18 | 2023-06-30 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| CA3178291A1 (fr) | 2016-08-05 | 2018-04-12 | Estetra Srl | Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles |
| CN106336444A (zh) * | 2016-08-23 | 2017-01-18 | 国家卫生计生委科学技术研究所 | 一种新晶型炔雌醇 |
| CR20200486A (es) | 2018-04-19 | 2021-01-27 | Estetra Sprl | Compuestos y sus usos para aliviar los síntomas asociados a la menopausa |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE61236B1 (en) * | 1986-07-15 | 1994-10-19 | American Home Prod | Combination dosage form for pre-menopausal women |
| ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
| US6083528A (en) * | 1995-09-28 | 2000-07-04 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| CA2234817A1 (fr) * | 1995-10-27 | 1997-05-01 | Mandana Asgharnejad | Formulation de secretagogue stimulant la secretion de l'hormone de croissance, destinee a etre granulee par voie humide |
| CN1122456C (zh) | 1996-01-31 | 2003-10-01 | 南亚拉巴马医学科学基金会 | 含有天然的还原叶酸盐异构体的食品和维生素制品 |
| CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| UA68365C2 (en) * | 1997-11-06 | 2004-08-16 | Wyeth Corp | Peroral contraception by combination of anti-estrogen and progestin |
| CN1240387C (zh) * | 1998-04-17 | 2006-02-08 | 奥索一麦克尼尔药品公司 | 含有叶酸的药用组合物及其用途和给药系统 |
| US7014865B1 (en) | 1998-10-19 | 2006-03-21 | Merck Patent Gmbh | Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid |
| JP2002527484A (ja) * | 1998-10-19 | 2002-08-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤 |
| CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| HU225779B1 (en) | 1999-07-28 | 2007-08-28 | Chinoin Gyogyszer Es Vegyeszet | Pharmaceutical composition containing paracetamol and drotaverine and process for producing it |
| US6787531B1 (en) | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| EP1598069B1 (fr) | 1999-08-31 | 2009-04-22 | Bayer Schering Pharma Aktiengesellschaft | Combinaison pharmaceutique d'éthinylestradiol et de drospirénone comme contraceptif |
| US6479545B1 (en) | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| DE10022510A1 (de) * | 2000-05-10 | 2001-11-15 | Basf Ag | Zusammensetzungen enthaltend Folsäure und reduziertes Folat |
| US20020094970A1 (en) * | 2000-12-14 | 2002-07-18 | Ronenn Roubenoff | Compositions and methods for treating an arthritic condition |
| US20030045510A1 (en) * | 2000-12-15 | 2003-03-06 | Schloss Caroline Maxine | Estrogen-plus |
| EP1216713A1 (fr) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions de complexes de estrogen-cyclodextrine |
| US20040220118A1 (en) * | 2001-02-02 | 2004-11-04 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
| US20060034954A1 (en) * | 2001-02-02 | 2006-02-16 | Bland Jeffrey S | Medical composition for balancing bodily processes |
| CA2476940C (fr) * | 2002-02-21 | 2011-11-01 | Bayer Intellectual Property Gmbh | Compositions pharmaceutiques contenant un ou plusieurs steroides, un ou plusieurs tetrahydrofolates et de la vitamine b12 |
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
-
2006
- 2006-05-11 UY UY29527A patent/UY29527A1/es not_active Application Discontinuation
- 2006-05-12 SV SV2006002527A patent/SV2008002527A/es active IP Right Grant
- 2006-05-12 AR ARP060101915A patent/AR054123A1/es not_active Application Discontinuation
- 2006-05-12 DO DO2006000110A patent/DOP2006000110A/es unknown
- 2006-05-12 GT GT200600200A patent/GT200600200A/es unknown
- 2006-05-12 TW TW095116905A patent/TWI380820B/zh active
- 2006-05-12 PE PE2006000504A patent/PE20061415A1/es active IP Right Grant
- 2006-05-15 MY MYPI20062228A patent/MY147362A/en unknown
- 2006-05-15 AT AT09075120T patent/ATE555791T1/de active
- 2006-05-15 KR KR1020077029090A patent/KR20080028369A/ko not_active Ceased
- 2006-05-15 NO NO20076408A patent/NO345807B1/no unknown
- 2006-05-15 CN CN2006800164109A patent/CN101198332B/zh not_active Expired - Lifetime
- 2006-05-15 RS RSP-2009/0327A patent/RS50972B/sr unknown
- 2006-05-15 SG SG201007499-5A patent/SG169973A1/en unknown
- 2006-05-15 EA EA200901393A patent/EA028530B1/ru not_active IP Right Cessation
- 2006-05-15 CN CN2010101564516A patent/CN101954083A/zh active Pending
- 2006-05-15 SI SI200631375T patent/SI2116249T1/sl unknown
- 2006-05-15 PL PL09075120T patent/PL2116249T3/pl unknown
- 2006-05-15 DK DK09075120.7T patent/DK2116249T3/da active
- 2006-05-15 PT PT06753787T patent/PT1888077E/pt unknown
- 2006-05-15 ES ES09075120T patent/ES2387525T5/es not_active Expired - Lifetime
- 2006-05-15 EP EP09075120.7A patent/EP2116249B2/fr not_active Expired - Lifetime
- 2006-05-15 CA CA2608639A patent/CA2608639C/fr not_active Expired - Fee Related
- 2006-05-15 HR HR20090418T patent/HRP20090418T1/xx unknown
- 2006-05-15 SI SI200630360T patent/SI1888077T1/sl unknown
- 2006-05-15 RS RS20120325A patent/RS52651B/sr unknown
- 2006-05-15 AT AT06753787T patent/ATE429917T1/de active
- 2006-05-15 ES ES06753787T patent/ES2325600T3/es not_active Expired - Lifetime
- 2006-05-15 DK DK06753787T patent/DK1888077T3/da active
- 2006-05-15 KR KR1020147010192A patent/KR101598735B1/ko not_active Expired - Lifetime
- 2006-05-15 AU AU2006245921A patent/AU2006245921A1/en not_active Abandoned
- 2006-05-15 EP EP06753787A patent/EP1888077B1/fr not_active Expired - Lifetime
- 2006-05-15 EP EP10185658A patent/EP2298307A1/fr not_active Withdrawn
- 2006-05-15 DE DE502006003617T patent/DE502006003617D1/de not_active Expired - Lifetime
- 2006-05-15 PT PT09075120T patent/PT2116249E/pt unknown
- 2006-05-15 PL PL06753787T patent/PL1888077T3/pl unknown
- 2006-05-15 BR BRPI0611443A patent/BRPI0611443B8/pt active IP Right Grant
- 2006-05-15 JP JP2008510518A patent/JP2008540482A/ja not_active Withdrawn
- 2006-05-15 EA EA200702349A patent/EA014664B1/ru active Protection Beyond IP Right Term
- 2006-05-15 WO PCT/EP2006/004858 patent/WO2006120035A2/fr not_active Ceased
-
2007
- 2007-11-12 US US11/938,688 patent/US20080160004A1/en not_active Abandoned
- 2007-11-12 TN TNP2007000418A patent/TNSN07418A1/en unknown
- 2007-11-13 MA MA30367A patent/MA29448B1/fr unknown
- 2007-11-13 IL IL187340A patent/IL187340A/en active IP Right Grant
- 2007-11-16 CR CR9531A patent/CR9531A/es not_active Application Discontinuation
- 2007-12-11 EC EC2007008001A patent/ECSP078001A/es unknown
- 2007-12-12 ZA ZA2007/10811A patent/ZA200710811B/en unknown
-
2009
- 2009-07-28 CY CY20091100804T patent/CY1109261T1/el unknown
- 2009-12-14 ZA ZA2009/08894A patent/ZA200908894B/en unknown
- 2009-12-18 CL CL2009002187A patent/CL2009002187A1/es unknown
-
2010
- 2010-09-21 CL CL2010000989A patent/CL2010000989A1/es unknown
-
2012
- 2012-08-02 CY CY20121100689T patent/CY1114403T1/el unknown
-
2013
- 2013-02-18 JP JP2013029277A patent/JP5883810B2/ja not_active Expired - Lifetime
-
2015
- 2015-12-10 US US14/965,173 patent/US10463666B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN07418A1 (en) | Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate | |
| Gerber et al. | Carcinogenicity, mutagenicity and teratogenicity of manganese compounds | |
| Kerr et al. | Alterations in the endocannabinoid system in the rat valproic acid model of autism | |
| Zourgui et al. | Cactus (Opuntia ficus-indica) cladodes prevent oxidative damage induced by the mycotoxin zearalenone in Balb/C mice | |
| Haque et al. | Low serum selenium concentration is associated with preeclampsia in pregnant women from Bangladesh | |
| Morris | Vitamin D: a hormone for all seasons-how much is enough? Understanding the new pressures | |
| Naber et al. | Genetics of human arterial hypertension | |
| WO2004059293A3 (fr) | Marqueurs de diagnostic differentiel et procedes d'utilisation | |
| Koz et al. | Effects of maternal hyperhomocysteinemia induced by methionine intake on oxidative stress and apoptosis in pup rat brain | |
| Bahadir et al. | Investigation of MTHFR C677T gene polymorphism, biochemical and clinical parameters in Turkish migraine patients: association with allodynia and fatigue | |
| Martínez et al. | Impact of early developmental arsenic exposure on promotor CpG-island methylation of genes involved in neuronal plasticity | |
| Selvaratnam et al. | Male rat germ cells display age-dependent and cell-specific susceptibility in response to oxidative stress challenges | |
| Thomas et al. | Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome | |
| Yazdanpanah et al. | Low dietary riboflavin but not folate predicts increased fracture risk in postmenopausal women homozygous for the MTHFR 677 T allele | |
| Dam et al. | Elevated skeletal muscle apoptotic signaling following glutathione depletion | |
| Ali et al. | Impact of arsenic on testosterone synthesis pathway and sperm production in mice | |
| Teixeira-Gomes et al. | Frailty syndrome, biomarkers and environmental factors–a pilot study | |
| Abelaira et al. | Ketamine exhibits different neuroanatomical profile after mammalian target of rapamycin inhibition in the prefrontal cortex: the role of inflammation and oxidative stress | |
| Li et al. | Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy | |
| Krstic et al. | Early life vitamin D depletion and mechanical loading determine methylation changes in the RUNX2, RXRA, and osterix promoters in mice | |
| Winstanley et al. | Drinking water quality impacts oocyte viability and embryo development | |
| Karakantza et al. | Inheritance and perinatal consequences of inherited thrombophilia in Greece | |
| Abd El Aal et al. | Serum vitamin D level may be a novel potential risk factor for premature ejaculation: a comparative study | |
| Wallace et al. | Dysregulated actin dynamics in activated PI3Kδ syndrome | |
| Brunyanszki et al. | Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress |